Enters the inhaler market in Russia with approval of Salmecort MDI inhaler
Glenmark Pharmaceuticals has received approval for Salmecort (Salmeterol+Fluticasone) MDI inhaler, from the Ministry of Health (MoH), Russia. The combination preparation contains salmeterol xinafoate and fluticasone propionate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). The approval is for 25mcg+50mcg/ dose, 25 mcg + 125 mcg/ dose and 25 mcg + 250 mcg/ dose formulation strengths.
The approval marks Glenmark’s entry into the respiratory inhaler market in Russia. According to IMS, the total inhaler market in Russia is estimated to be around $283 million, out of which the total MDI market is valued at around $107 million. Salmecort is expected to be available in the Russian market in Q2 FY 2015-16.
EP News Bureau – Mumbai